A phase 3 study to evaluate the Efficacy and Safety of KEVEYIS (dichlorphenamide) in Adolescent Patients with Primary Periodic Paralysis.
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs Diclofenamide (Primary)
- Indications Paralysis
- Focus Therapeutic Use
- Acronyms Study 2
- 09 Mar 2018 New trial record
- 05 Mar 2018 According to a Strongbridge Biopharma media release, Emma Ciafaloni, M.D, professor of neurology and pediatrics at the University of Rochester Medical Center is the principal investigator of the study.
- 05 Mar 2018 Results presented in the Strongbridge Biopharma Media Release.